News
Citigroup says shares of this obesity drug biotech could nearly double
Published
6 months agoon
By
admin
BioAge Labs shares have ample room to run as the biotechnology firm’s obesity treatment is poised to gain traction in the booming weight management solutions market, according to Citigroup. The bank upgraded BioAge to buy from neutral on Wednesday, doubling its 12-month price target on the stock to $10 from $5, implying 89% upside from Tuesday’s close. “Given guidance for multiple [obesity product] and third-party data readouts over the next ~12-15 months, we believe it’s appropriate to upgrade BIOA,” Citi analyst Samantha Semenkow said in a note to clients. “We see the upcoming clinical data from both BioAge and competitors as potential stock moving catalysts.” BioAge is likely to see upside from its novel obesity treatment, BGE-102, a highly potent small-molecule NLRP3 inhibitor, according to Citi. The company began a Phase I study of the treatment last summer. BGE-102 could be prescribed on its own or in combination with an oral GLP-1 drug such as Rybelsus, a feature that could boost its market penetration. “In our assessment, BGE-102 look[s] promising as a potentially differentiated NLRP3 inhibitor that could serve as a combo option with oral GLP1s and/or as a monotherapy,” Semenkow wrote. GLP-1 use has increased significantly over the past few years. In a 2024 poll, one in eight adults reported using GLP-1 drugs, with more than 40% of diabetics aged 18 or older saying they’d used a GLP-1 product, according to non-profit research organization KFF, formerly the Kaiser Family Foundation . Citi’s upgrade is at odds with the consensus on Wall Street. Three analysts have a hold on BioAge shares, while one analyst has rated the stock underperform, LSEG data shows. BioAge’s stock iis ahead 13% on Wednesday, bringing the gain over the past six months to 43%.
This industrial giant is emerging as a big AI play, says Wells Fargo
Novo Nordisk’s strategy tested as investors push back on board revamp
Alibaba plans AI subscriptions, stablecoin-like payments with JPMorgan
UK borrowing costs spike on report government to scrap plans to raise income tax
Trump’s threatened the BBC with a $1B lawsuit: Here’s what’s going on
UBS’s picks for global returns next year
Wells Fargo sees Caterpillar continuing to roar higher, emerging as an artificial intelligence play. The bank initiated shares of...
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic...
Key Points Alibaba plans to use “tokenization” of payments for cross-border transactions in its business-to-business arm. Kuo Zhang, president...
Rachel Reeves, U.K. chancellor of the exchequer, delivers a speech in London, UK, on Tuesday, Nov. 4, 2025. Bloomberg...
US President Donald Trump speaks to reporters as he arrives at Palm Beach International Airport on Oct. 31,...
Investors looking for global diversification opportunities should look to a specific subset of stocks in Europe, according to UBS...
Eakarat Buanoi | Istock | Getty Images LISBON, Portugal — Top tech executives told CNBC they’re concerned about...
Tan Su Shan, deputy chief executive officer and managing director of institutional banking at DBS Group Holdings Ltd., speaks during...
CHENGDU, CHINA – OCTOBER 18: People walk past the Louis Vuitton store at Taikoo Li, a high-end shopping area that...
The United States said Thursday it will remove tariffs on some foods and other imports from Argentina, Ecuador, Guatemala and...
